Table 2.
Controls | Supplemented | P | |
---|---|---|---|
Gender | |||
Male | 8/8 (100.0%) | 15/18 (83.3%) | 0.529 |
Female | 0/8 (0.0%) | 3/18 (16.7%) | |
Age (years ± SD) | 62.0 ± 6.2 | 65.8 ± 10.1 | 0.337 |
Chemotherapy cycles | 3.0 ± 1.6 | 3.6 ± 1.5 | 0.365 |
Cisplatin dose (mg) | 456.8 ± 195.5 | 464.6 ± 110.7 | 0.897 |
Metastases | 2/8 (25.0%) | 2/18 (11.1%) | 0.563 |
Concomitant radiotherapy | 6/8 (75.0%) | 12/18 (66.7%) | 1.000 |
Previous otologic pathologies | 1/8 (12.5%) | 3/18 (16.7%) | 1.000 |
Previous tinnitus | 1/8 (12.5%) | 2/18 (11.1%) | 1.000 |